'Pro­tein print­ing' Ab­Sci se­cures $125M crossover as it ex­pands syn­thet­ic bi­ol­o­gy am­bi­tions

Two months af­ter ac­quir­ing an AI en­gine it claims can po­ten­tial­ly speed up drug de­vel­op­ment by “un­prece­dent­ed” lev­els,” Ab­Sci has se­cured a hefty crossover round to in­te­grate the en­gine in­to the com­pa­ny. And it has CEO Sean Mc­Clain con­sid­er­ing an even­tu­al IPO.

Ab­Sci closed a $125 mil­lion crossover round Tues­day morn­ing as it trains the De­n­ovi­um AI plat­form to ac­count for man­u­fac­tura­bil­i­ty, func­tion­al­i­ty and ex­pres­sion of new com­pounds, in ad­di­tion to op­ti­miz­ing the com­pounds them­selves. Though the com­pa­ny isn’t de­vel­op­ing any in­ter­nal pipeline, Mc­Clain be­lieves De­n­ovi­um will help Ab­Sci ul­ti­mate­ly short­en the over­all R&D process.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER